Generate Biomedicines (GENB) investor relations material

Executive summary

• Closed IPO on March 2, 2026, raising $369.3 million in net proceeds; all preferred stock converted to common stock.

• Advanced GB-0895 (Phase 3 for severe asthma, Phase 1b in COPD), GB-4362 (Phase 1, FDA Fast Track, first dosing mid-2026), and GB-5267 (Phase 1, first dosing H2 2026, targeting ovarian cancer).

• No products approved for sale; revenue derived from collaboration agreements with Novartis and Amgen.

• Collaboration with Roswell Park Comprehensive Cancer Center for GB-5267.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $516.6 million as of March 31, 2026, up from $221.5 million at year-end 2025.

• Collaboration revenue was $7.2 million for Q1 2026, down from $8.8 million in Q1 2025.

• Net loss attributable to common stockholders was $69.2 million for Q1 2026, compared to $53.3 million in Q1 2025.

• Research and development expenses increased to $57.8 million (Q1 2026) from $46.8 million (Q1 2025), mainly due to GB-0895 clinical advancement and higher personnel costs.

• General and administrative expenses rose to $13.5 million from $10.1 million year-over-year, driven by stock-based compensation and public company costs.

Outlook and guidance

• Current cash resources, bolstered by IPO proceeds, expected to fund operations into the first half of 2028.

• Anticipates continued increases in operating losses as clinical and preclinical programs expand.

• Expects to require additional capital to support long-term operations and future commercialization.